<?xml version='1.0' encoding='utf-8'?>
<document id="18609447"><sentence text="In vitro metabolism of a novel PPAR gamma agonist, KR-62980, and its stereoisomer, KR-63198, in human liver microsomes and by recombinant cytochrome P450s." /><sentence text="1" /><sentence text=" KR-62980 and its stereoisomer KR-63198 are novel and selective peroxisome proliferator-activated receptor gamma (PPAR gamma) modulators with activity profiles different from that of rosiglitazone"><entity charOffset="183-196" id="DDI-PubMed.18609447.s3.e0" text="rosiglitazone" /></sentence><sentence text=" This study was performed to identify the major metabolic pathways for KR-62980 and KR-63198 in human liver microsomes" /><sentence text=" 2" /><sentence text=" Human liver microsomal incubation of KR-62980 and KR-63198 in the presence of a beta-nicotinamide adenine dinucleotide phosphate (NADPH)-generating system resulted in hydroxy metabolite formation"><entity charOffset="81-129" id="DDI-PubMed.18609447.s6.e0" text="beta-nicotinamide adenine dinucleotide phosphate" /></sentence><sentence text=" In addition, the specific cytochrome P450s (CYPs) responsible for KR-62980 and KR-63198 hydroxylation were identified by using a combination of chemical inhibition in human liver microsomes and metabolism by recombinant P450s" /><sentence text=" It is shown that CYP1A2, CYP2D6, CYP3A4, and CYP3A5 are the predominant enzymes in the hydroxylation of KR-62980 and KR-63198"><entity charOffset="118-126" id="DDI-PubMed.18609447.s8.e0" text="KR-63198" /></sentence><sentence text=" 3" /><sentence text=" The intrinsic clearance through hydroxylation was consistently and significantly higher for KR-62980 than for KR-63198, indicating metabolic stereoselectivity (CL(int) of 0" /><sentence text="012 +/- 0" /><sentence text="001 versus 0" /><sentence text="004 +/- 0" /><sentence text="001 microl min(-1) pmol(-1) P450, respectively)" /><sentence text=" 4" /><sentence text=" In a drug-drug interaction study, KR-62980 and KR-63198 had no effect on the activities of the P450s tested (IC(50) &gt; 50 microM), suggesting that in clinical interactions between KR-62980 and KR-63198 the P450s tested would not be expected"><entity charOffset="48-56" id="DDI-PubMed.18609447.s16.e0" text="KR-63198" /></sentence><sentence text="" /></document>